In the fast-moving world of clinical development, biotech innovators face immense pressure to design efficient, evidence-based studies that attract investor confidence. This case study reveals how MMS Holdings leveraged KerusCloud®, a cutting-edge simulation-guided study design platform, to help a small biotech de-risk its RSV program, optimize study designs, and accelerate funding success.

Whether you’re leading early-stage development, evaluating new protocols, or presenting to investors, this resource shows how data-driven study simulations can transform complex challenges into strategic opportunities enabling you to reduce costs, shorten timelines, and increase confidence in your clinical strategy.

Key Benefits / What You’ll Learn:

• Understand how KerusCloud® quantified study success probability through simulation-based design.
• See how optimized designs reduced RSV study timelines from 3 years to 1 year.
• Learn how robust data insights increased the probability of program success.
• Explore how evidence-driven modeling supported a successful $30M funding round.
• Discover how simulation frameworks ensure smarter, more adaptive trial strategies.

Created by MMS biostatistics experts, trusted globally for delivering data-driven trial design strategies that accelerate development and investment readiness.